Pharmaceutical Firms Adopt Automated Plate Inspection
AstraZeneca and CSL are integrating APAS units to improve the accuracy of microbial impurity detection in sterile facilities.
Updated on Oct. 27, 2026 in Biotech
Live Poll
Do you trust automated technology more than human judgment for critical safety tasks?
AstraZeneca and CSL have publicly adopted Clever Culture Systems' APAS automated plate-reading technology to enhance quality control in sterile manufacturing. The units use code-based image recognition to replace human inspection for identifying microbial impurities on agar plates.
Why it matters
By automating the plate-reading process, pharmaceutical manufacturers are attempting to reduce the variability and fatigue associated with human visual inspection. This transition toward centralized quality control is intended to boost operational efficiency across large-scale sterile production environments.
The APAS Independence unit, which costs US$350,000, automates the processing of agar plates to monitor for contaminants. It replaces manual oversight with code that identifies organisms on each plate, supporting the high-throughput needs of facilities like CSL, which produces 1 million agar plates annually.
The players
AstraZeneca
A global pharmaceutical company that focuses on oncology, cardiovascular, and biopharmaceuticals with a high-throughput manufacturing pipeline.
CSL
A global biotechnology leader specializing in protein-based therapies and vaccine manufacturing with extensive plant infrastructure.
Clever Culture Systems
A technology developer specializing in automated microbiology and imaging solutions for industrial and clinical quality control.
PSC Biotech
A life sciences consultancy and service provider that recently entered a lead-generation agreement for APAS units.
The details
The APAS Independence device functions by imaging agar plates—petri dishes containing a growth medium—to detect microbial growth. Instead of human technicians, an automated vision system uses algorithms to scan for colony formation and classify impurities, reducing the risk of human error in sterile environments. The process allows facilities to maintain rigorous quality control while scaling up production volumes.
Timeline
Over the past two years, Clever Culture Systems pivoted its strategy to target large pharmaceutical companies.
As of October 2026, AstraZeneca has integrated 12 APAS units across its facilities.
The Tech Race
This move highlights the competitive race to automate quality control in sterile manufacturing, pitting APAS technology against established manual processes. As companies like CSL and AstraZeneca scale production, the ability to automate routine inspection becomes a critical differentiator for operational throughput.
The adoption of these units by top-tier pharmaceutical companies will likely accelerate once mid-tier firms begin incorporating similar technology. While specific timelines for widespread rollout vary, the move signals an industry-wide transition toward automated, high-precision impurity testing.
The takeaway
The pivot of major pharmaceutical players toward automated plate inspection suggests that manual quality control is increasingly seen as a scalability constraint. Industry observers should watch for Clever Culture's incremental sales growth among mid-tier firms to see how quickly this tech reaches the broader market.
Further reading
For more on industry-wide trends in lab automation, visit our /tech/biotech/ section.
Source note: This article includes information reported by Stockhead.
Live Poll
Do you trust automated technology more than human judgment for critical safety tasks?
